Sanifit starts Phase Ib/II with SNF472 in dialysis patients

Sanifit Laboratories has obtained the authorization from the AEMPS and the ethics committee to initiate Phase Ib/II studies in Hospital Clinic, Barcelona, Spain. This double-blind, placebo-controlled trial will evaluate the safety, pharmacokinetics and pharmacodynamics of SNF472 in dialysis patients up to one month of treatment. SNF472 is an experimental drug for the treatment of vascular calcification and calciphylaxis (CUA), which has demonstrated an excellent safety and PK-PD profile   in clinical trials with healthy volunteers.